Sugi Predict

Sugi Predict / Compounds / SCHEMBL1728378

SCHEMBL1728378

SCHEMBL1728378

O=C(OC[C@H]1O[C@H](Br)[C@H](OC(=O)c2ccccc2)[C@@H](OC(=O)c2ccccc2)[C@@H]1OC(=O)c1ccccc1)c1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 2/20 0.54
▸ POLB P06746 2/20 0.54
▸ MEN1 O00255 1/20 0.54
▸ KMT2A Q03164 1/20 0.54
▸ PTPN1 P18031 4/20 0.49
▸ PTPN2 P17706 1/20 0.46
▸ PTPN11 Q06124 1/20 0.46
▸ CA1 P00915 2/20 0.46
▸ CA2 P00918 2/20 0.46
▸ CA9 Q16790 1/20 0.46
▸ TSHR P16473 1/20 0.46
▸ ALDH1A1 P00352 1/20 0.45
▸ F11 P03951 2/20 0.45
▸ MAPK1 P28482 2/20 0.45
▸ TMPRSS2 O15393 1/20 0.45
▸ PDE5A O76074 1/20 0.45
▸ HMGCR P04035 1/20 0.45
▸ CYP1A2 P05177 1/20 0.45
▸ LCK P06239 1/20 0.45
▸ FYN P06241 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1726977 1.00 USP2 (0.54) USP2POLBMEN1KMT2APTPN1
SCHEMBL17620221 1.00 USP2 (0.54) USP2POLBMEN1KMT2APTPN1
SCHEMBL17620173 1.00 USP2 (0.54) USP2POLBMEN1KMT2APTPN1
SCHEMBL17620209 1.00 USP2 (0.54) USP2POLBMEN1KMT2APTPN1
SCHEMBL3663518 1.00 USP2 (0.54) USP2POLBMEN1KMT2APTPN1
SCHEMBL3272584 1.00 USP2 (0.54) USP2POLBMEN1KMT2APTPN1
SCHEMBL6022376 1.00 USP2 (0.54) USP2POLBMEN1KMT2APTPN1
SCHEMBL3663517 1.00 USP2 (0.54) USP2POLBMEN1KMT2APTPN1
SCHEMBL14103187 1.00 USP2 (0.54) USP2POLBMEN1KMT2APTPN1
SCHEMBL2493929 0.99 USP2 (0.55) USP2POLBMEN1KMT2APTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110224159-A1 BIDESMOSIDIC BETULIN AND BETULINIC ACID DERIVATIVES AND USES THEREOF AS ANTITUMOR AGENTS Universite du Quebec a Chicoutime (CA) 2011-09-15 — — US claimed
EP-2340257-A1 BIDESMOSIDIC BETULIN AND BETULINIC ACID DERIVATIVES AND USES THEREOF AS ANTITUMOR AGENTS Université du Québec à Chicoutimi (CA) 2011-07-06 — — EP claimed
WO-2010028487-A1 BIDESMOSIDIC BETULIN AND BETULINIC ACID DERIVATIVES AND USES THEREOF AS ANTITUMOR AGENTS UNIVERSITÉ DU QUÉBEC À CHICOUTIMI (CA) 2010-03-18 — — WO claimed
US-7435816-B2 Synthesis of solanum glycosides GLYCOMED SCIENCES (KY) 2008-10-14 — — US claimed
EP-1421100-B1 CHEMICAL SYNTHESIS OF SOLAMARGINE GLYCOMED SCIENCES LTD (KY) 2008-07-09 — — EP claimed
US-20080039628-A1 Synthesis of Solanum Glycosides GLYCOMED SCIENCES (KY) 2008-02-14 — — US claimed
EP-1618122-A1 SYNTHESIS OF SOLANUM GLYCOSIDES GlycoMed Sciences (UK) Limited, c/o Consolidated Capital Limited (GB) 2006-01-25 — — EP claimed
WO-2004096830-A1 SYNTHESIS OF SOLANUM GLYCOSIDES GLYCOMED SCIENCES (UK) LIMITED (GB) 2004-11-11 — — WO claimed
EP-1421100-A1 CHEMICAL SYNTHESIS OF SOLAMARGINE GlycoMed Sciences Limited (AU) 2004-05-26 — — EP claimed
WO-2003018604-A1 SYNTHESIS OF SOLANUM GLYCOSIDES GLYCOMED SCIENCES LIMITED (AU) 2003-03-06 — — WO claimed
CN-119899222-A Alkyl N-glycoside compound and synthesis method thereof 西安交通大学 2025-04-29 — — CN disclosed
US-11319338-B2 Timosaponin compounds GOLDPORP PHARMA LIMITED (HK) 2022-05-03 — — US disclosed
EP-2963048-B1 METHOD FOR PRODUCING ALPHA-HALO-TETRAACYL GLUCOSE MITSUBISHI TANABE PHARMA CORP (JP) 2020-11-18 — — EP disclosed
US-20200181187-A1 PROCESS FOR THE PREPARATION OF (S,S)-SECOISOLARICIRESINOL DIGLUCOSIDE AND (R,R)-SECOISOLARICIRESINOL DIGLUCOSIDE LIGNAMED LLC (US) 2020-06-11 — — US disclosed
EP-3638220-A1 PROCESS FOR THE PREPARATION OF (S,S LignaMed, LLC (US) 2020-04-22 — — EP disclosed
WO-1995012219-A1 STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS UNISEARCH LIMITED (AU) 1995-05-04 — — WO disclosed
WO-1995008558-A1 NOVEL DEOXY AND OXYGEN-SUBSTITUTED SUGAR-CONTAINING 14-AMINOSTEROID COMPOUNDS THE PROCTER & GAMBLE COMPANY (US) 1995-03-30 — — WO disclosed
WO-1995005182-A1 BRIDGED OLIGOSACCHARIDES AND SULFATED DERIVATIVES THEREOF GLYCOMED INCORPORATED (US) 1995-02-23 — — WO disclosed
WO-1994015947-A1 NOVEL COLON- OR ILEUM-SPECIFIC STEROID DERIVATIVES ASTRA AKTIEBOLAG (SE) 1994-07-21 — — WO disclosed
WO-1993020078-A1 PHARMACEUTICALLY ACTIVE BICYCLIC-HETEROCYCLIC AMINES THE UPJOHN COMPANY (US) 1993-10-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200181187-A1 PROCESS FOR THE PREPARATION OF (S,S)-SECOISOLARICIRESINOL DIGLUCOSIDE AND (R,R)-SECOISOLARICIRESINOL DIGLUCOSIDE LSS, STS, SRM USP2 2142/4885POLB 1943/4885MEN1 3381/4885
US-11319338-B2 Timosaponin compounds APP, IAPP, BACE1 USP2 4673/4885POLB 3050/4885MEN1 1058/4885
US-20110224159-A1 BIDESMOSIDIC BETULIN AND BETULINIC ACID DERIVATIVES AND USES THEREOF AS ANTITUMOR AGENTS BET1, SI, ERG28 USP2 4685/4885POLB 3875/4885MEN1 309/4885
US-20080039628-A1 Synthesis of Solanum Glycosides B3GNT2, ST6GAL1, ST3GAL3 USP2 1651/4885POLB 3976/4885MEN1 2231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.